Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?
We aimed to investigate the association between the different antiphospholipid antibodies (aPL) and both systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) manifestations. Patients from the RELESSER registry, a Spanish retrospective, cross-sectional, forty-five hospital registry...
Gespeichert in:
Veröffentlicht in: | Clinical and Experimental Rheumatology 2021-05, Vol.39 (3), p.555-563 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 563 |
---|---|
container_issue | 3 |
container_start_page | 555 |
container_title | Clinical and Experimental Rheumatology |
container_volume | 39 |
creator | Riancho-Zarrabeitia, Leyre Martínez-Taboada, Víctor M Rúa-Figueroa, Iñigo Alonso, Fernando Galindo-Izquierdo, María Ovalles, Juan Olivé-Marqués, Alejandro Mena Vázquez, Natalia Calvo-Alén, Jaime Menor Almagro, Raúl Tomero Muriel, Eva Uriarte Isacelaya, Esther Boteanu, Alina Andres, Mariano Freire González, Mercedes Santos Soler, Gregorio Ruiz-Lucea, Maria Esther Ibáñez-Barceló, Mónica Castellví, Iván Galisteo, Carlos Quevedo Vila, Víctor Raya, Enrique Narváez, Javier Expósito, Lorena Hernández Beriaín, José A Horcada, Loreto Aurrecoechea, Elena Pego Reigosa, José M |
description | We aimed to investigate the association between the different antiphospholipid antibodies (aPL) and both systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) manifestations.
Patients from the RELESSER registry, a Spanish retrospective, cross-sectional, forty-five hospital registry of adult SLE patients, were included.
Out of a total of 3,658 SLE patients, 1372 were aPL positive (555 of them fulfilled criteria for APS). All aPL types showed a negative association with cutaneous SLE manifestations. Lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) were both associated with haematological, ophthalmological and neuropsychiatric manifestations. IgG isotypes were associated with a higher risk of lupus manifestations compared with IgM. We found that the risk of neuropsychiatric and ophthalmological manifestations significantly increased with a higher number of positive aPL whereas the risk of cutaneous symptoms showed a negative correlation. All types of aPL, and more strongly LA, were associated with non-criteria antiphospholipid syndrome (APS) manifestations such as thrombocytopenia and haemolytic anaemia. Moreover, LA and aCL (particularly IgG isotype) were also associated with Libman-Sacks endocarditis and cognitive impairment. This association was stronger with more than one positive aPL. All types of aPL were also associated with classic APS manifestations, although LA, IgG isotypes, and patients with more than one aPL displayed a higher risk.
There is a hierarchy for aPL and the risk of APS and SLE manifestations. aCL, and especially LA, confer a higher risk for major organ involvement in SLE. IgG isotypes seem to have a more important role. The load of aPL confer a higher risk for APS and certain SLE manifestations. |
doi_str_mv | 10.55563/clinexprheumatol/9kxexc |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2436875925</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2436875925</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-57334988f4554714562609472f5ce5c44208870ac194338cb7118b8b7961cf613</originalsourceid><addsrcrecordid>eNpdkE1P3DAQhq0KVBbav1D5yCXF37FPFQIKlZC4gMQtcryTrsGJU0-Cdg_97w0s7aEHj2dG7zszegihnH3VWht5FlIcYDuWDcy9n3I6c89b2IYPZMW1kxVz9vGArJh0orLaPB6RY8QnxoTRpv5IjqSwwnJlV-T3ZaY-JeqHKY6bjMtLcYzrt0ab1xGQhjx0UOi0AYq-B1oiPtMuF9r7pyXm8tMPNA4vOb1AD8O05BR3OEEfA03zOCOFslvsr6fiUo1-iosOv30ih51PCJ_f_xPy8P3q_uKmur27_nFxflsFafRU6VpK5aztlNaq5kobYZhTteh0AB2UEszamvnAnZLShrbm3La2rZ3hoTNcnpDT_dyx5F8z4NT0EQOk5AfIMzZCSWNr7YRepHYvDSUjFuiascTel13DWfMGv_kffrOHv1i_vG-Z2x7W_4x_acs_fmaKUw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2436875925</pqid></control><display><type>article</type><title>Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?</title><source>Alma/SFX Local Collection</source><creator>Riancho-Zarrabeitia, Leyre ; Martínez-Taboada, Víctor M ; Rúa-Figueroa, Iñigo ; Alonso, Fernando ; Galindo-Izquierdo, María ; Ovalles, Juan ; Olivé-Marqués, Alejandro ; Mena Vázquez, Natalia ; Calvo-Alén, Jaime ; Menor Almagro, Raúl ; Tomero Muriel, Eva ; Uriarte Isacelaya, Esther ; Boteanu, Alina ; Andres, Mariano ; Freire González, Mercedes ; Santos Soler, Gregorio ; Ruiz-Lucea, Maria Esther ; Ibáñez-Barceló, Mónica ; Castellví, Iván ; Galisteo, Carlos ; Quevedo Vila, Víctor ; Raya, Enrique ; Narváez, Javier ; Expósito, Lorena ; Hernández Beriaín, José A ; Horcada, Loreto ; Aurrecoechea, Elena ; Pego Reigosa, José M</creator><creatorcontrib>Riancho-Zarrabeitia, Leyre ; Martínez-Taboada, Víctor M ; Rúa-Figueroa, Iñigo ; Alonso, Fernando ; Galindo-Izquierdo, María ; Ovalles, Juan ; Olivé-Marqués, Alejandro ; Mena Vázquez, Natalia ; Calvo-Alén, Jaime ; Menor Almagro, Raúl ; Tomero Muriel, Eva ; Uriarte Isacelaya, Esther ; Boteanu, Alina ; Andres, Mariano ; Freire González, Mercedes ; Santos Soler, Gregorio ; Ruiz-Lucea, Maria Esther ; Ibáñez-Barceló, Mónica ; Castellví, Iván ; Galisteo, Carlos ; Quevedo Vila, Víctor ; Raya, Enrique ; Narváez, Javier ; Expósito, Lorena ; Hernández Beriaín, José A ; Horcada, Loreto ; Aurrecoechea, Elena ; Pego Reigosa, José M</creatorcontrib><description>We aimed to investigate the association between the different antiphospholipid antibodies (aPL) and both systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) manifestations.
Patients from the RELESSER registry, a Spanish retrospective, cross-sectional, forty-five hospital registry of adult SLE patients, were included.
Out of a total of 3,658 SLE patients, 1372 were aPL positive (555 of them fulfilled criteria for APS). All aPL types showed a negative association with cutaneous SLE manifestations. Lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) were both associated with haematological, ophthalmological and neuropsychiatric manifestations. IgG isotypes were associated with a higher risk of lupus manifestations compared with IgM. We found that the risk of neuropsychiatric and ophthalmological manifestations significantly increased with a higher number of positive aPL whereas the risk of cutaneous symptoms showed a negative correlation. All types of aPL, and more strongly LA, were associated with non-criteria antiphospholipid syndrome (APS) manifestations such as thrombocytopenia and haemolytic anaemia. Moreover, LA and aCL (particularly IgG isotype) were also associated with Libman-Sacks endocarditis and cognitive impairment. This association was stronger with more than one positive aPL. All types of aPL were also associated with classic APS manifestations, although LA, IgG isotypes, and patients with more than one aPL displayed a higher risk.
There is a hierarchy for aPL and the risk of APS and SLE manifestations. aCL, and especially LA, confer a higher risk for major organ involvement in SLE. IgG isotypes seem to have a more important role. The load of aPL confer a higher risk for APS and certain SLE manifestations.</description><identifier>ISSN: 0392-856X</identifier><identifier>EISSN: 1593-098X</identifier><identifier>DOI: 10.55563/clinexprheumatol/9kxexc</identifier><identifier>PMID: 32828148</identifier><language>eng</language><publisher>Italy</publisher><ispartof>Clinical and Experimental Rheumatology, 2021-05, Vol.39 (3), p.555-563</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-57334988f4554714562609472f5ce5c44208870ac194338cb7118b8b7961cf613</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32828148$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Riancho-Zarrabeitia, Leyre</creatorcontrib><creatorcontrib>Martínez-Taboada, Víctor M</creatorcontrib><creatorcontrib>Rúa-Figueroa, Iñigo</creatorcontrib><creatorcontrib>Alonso, Fernando</creatorcontrib><creatorcontrib>Galindo-Izquierdo, María</creatorcontrib><creatorcontrib>Ovalles, Juan</creatorcontrib><creatorcontrib>Olivé-Marqués, Alejandro</creatorcontrib><creatorcontrib>Mena Vázquez, Natalia</creatorcontrib><creatorcontrib>Calvo-Alén, Jaime</creatorcontrib><creatorcontrib>Menor Almagro, Raúl</creatorcontrib><creatorcontrib>Tomero Muriel, Eva</creatorcontrib><creatorcontrib>Uriarte Isacelaya, Esther</creatorcontrib><creatorcontrib>Boteanu, Alina</creatorcontrib><creatorcontrib>Andres, Mariano</creatorcontrib><creatorcontrib>Freire González, Mercedes</creatorcontrib><creatorcontrib>Santos Soler, Gregorio</creatorcontrib><creatorcontrib>Ruiz-Lucea, Maria Esther</creatorcontrib><creatorcontrib>Ibáñez-Barceló, Mónica</creatorcontrib><creatorcontrib>Castellví, Iván</creatorcontrib><creatorcontrib>Galisteo, Carlos</creatorcontrib><creatorcontrib>Quevedo Vila, Víctor</creatorcontrib><creatorcontrib>Raya, Enrique</creatorcontrib><creatorcontrib>Narváez, Javier</creatorcontrib><creatorcontrib>Expósito, Lorena</creatorcontrib><creatorcontrib>Hernández Beriaín, José A</creatorcontrib><creatorcontrib>Horcada, Loreto</creatorcontrib><creatorcontrib>Aurrecoechea, Elena</creatorcontrib><creatorcontrib>Pego Reigosa, José M</creatorcontrib><title>Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?</title><title>Clinical and Experimental Rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>We aimed to investigate the association between the different antiphospholipid antibodies (aPL) and both systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) manifestations.
Patients from the RELESSER registry, a Spanish retrospective, cross-sectional, forty-five hospital registry of adult SLE patients, were included.
Out of a total of 3,658 SLE patients, 1372 were aPL positive (555 of them fulfilled criteria for APS). All aPL types showed a negative association with cutaneous SLE manifestations. Lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) were both associated with haematological, ophthalmological and neuropsychiatric manifestations. IgG isotypes were associated with a higher risk of lupus manifestations compared with IgM. We found that the risk of neuropsychiatric and ophthalmological manifestations significantly increased with a higher number of positive aPL whereas the risk of cutaneous symptoms showed a negative correlation. All types of aPL, and more strongly LA, were associated with non-criteria antiphospholipid syndrome (APS) manifestations such as thrombocytopenia and haemolytic anaemia. Moreover, LA and aCL (particularly IgG isotype) were also associated with Libman-Sacks endocarditis and cognitive impairment. This association was stronger with more than one positive aPL. All types of aPL were also associated with classic APS manifestations, although LA, IgG isotypes, and patients with more than one aPL displayed a higher risk.
There is a hierarchy for aPL and the risk of APS and SLE manifestations. aCL, and especially LA, confer a higher risk for major organ involvement in SLE. IgG isotypes seem to have a more important role. The load of aPL confer a higher risk for APS and certain SLE manifestations.</description><issn>0392-856X</issn><issn>1593-098X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdkE1P3DAQhq0KVBbav1D5yCXF37FPFQIKlZC4gMQtcryTrsGJU0-Cdg_97w0s7aEHj2dG7zszegihnH3VWht5FlIcYDuWDcy9n3I6c89b2IYPZMW1kxVz9vGArJh0orLaPB6RY8QnxoTRpv5IjqSwwnJlV-T3ZaY-JeqHKY6bjMtLcYzrt0ab1xGQhjx0UOi0AYq-B1oiPtMuF9r7pyXm8tMPNA4vOb1AD8O05BR3OEEfA03zOCOFslvsr6fiUo1-iosOv30ih51PCJ_f_xPy8P3q_uKmur27_nFxflsFafRU6VpK5aztlNaq5kobYZhTteh0AB2UEszamvnAnZLShrbm3La2rZ3hoTNcnpDT_dyx5F8z4NT0EQOk5AfIMzZCSWNr7YRepHYvDSUjFuiascTel13DWfMGv_kffrOHv1i_vG-Z2x7W_4x_acs_fmaKUw</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Riancho-Zarrabeitia, Leyre</creator><creator>Martínez-Taboada, Víctor M</creator><creator>Rúa-Figueroa, Iñigo</creator><creator>Alonso, Fernando</creator><creator>Galindo-Izquierdo, María</creator><creator>Ovalles, Juan</creator><creator>Olivé-Marqués, Alejandro</creator><creator>Mena Vázquez, Natalia</creator><creator>Calvo-Alén, Jaime</creator><creator>Menor Almagro, Raúl</creator><creator>Tomero Muriel, Eva</creator><creator>Uriarte Isacelaya, Esther</creator><creator>Boteanu, Alina</creator><creator>Andres, Mariano</creator><creator>Freire González, Mercedes</creator><creator>Santos Soler, Gregorio</creator><creator>Ruiz-Lucea, Maria Esther</creator><creator>Ibáñez-Barceló, Mónica</creator><creator>Castellví, Iván</creator><creator>Galisteo, Carlos</creator><creator>Quevedo Vila, Víctor</creator><creator>Raya, Enrique</creator><creator>Narváez, Javier</creator><creator>Expósito, Lorena</creator><creator>Hernández Beriaín, José A</creator><creator>Horcada, Loreto</creator><creator>Aurrecoechea, Elena</creator><creator>Pego Reigosa, José M</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210501</creationdate><title>Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?</title><author>Riancho-Zarrabeitia, Leyre ; Martínez-Taboada, Víctor M ; Rúa-Figueroa, Iñigo ; Alonso, Fernando ; Galindo-Izquierdo, María ; Ovalles, Juan ; Olivé-Marqués, Alejandro ; Mena Vázquez, Natalia ; Calvo-Alén, Jaime ; Menor Almagro, Raúl ; Tomero Muriel, Eva ; Uriarte Isacelaya, Esther ; Boteanu, Alina ; Andres, Mariano ; Freire González, Mercedes ; Santos Soler, Gregorio ; Ruiz-Lucea, Maria Esther ; Ibáñez-Barceló, Mónica ; Castellví, Iván ; Galisteo, Carlos ; Quevedo Vila, Víctor ; Raya, Enrique ; Narváez, Javier ; Expósito, Lorena ; Hernández Beriaín, José A ; Horcada, Loreto ; Aurrecoechea, Elena ; Pego Reigosa, José M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-57334988f4554714562609472f5ce5c44208870ac194338cb7118b8b7961cf613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Riancho-Zarrabeitia, Leyre</creatorcontrib><creatorcontrib>Martínez-Taboada, Víctor M</creatorcontrib><creatorcontrib>Rúa-Figueroa, Iñigo</creatorcontrib><creatorcontrib>Alonso, Fernando</creatorcontrib><creatorcontrib>Galindo-Izquierdo, María</creatorcontrib><creatorcontrib>Ovalles, Juan</creatorcontrib><creatorcontrib>Olivé-Marqués, Alejandro</creatorcontrib><creatorcontrib>Mena Vázquez, Natalia</creatorcontrib><creatorcontrib>Calvo-Alén, Jaime</creatorcontrib><creatorcontrib>Menor Almagro, Raúl</creatorcontrib><creatorcontrib>Tomero Muriel, Eva</creatorcontrib><creatorcontrib>Uriarte Isacelaya, Esther</creatorcontrib><creatorcontrib>Boteanu, Alina</creatorcontrib><creatorcontrib>Andres, Mariano</creatorcontrib><creatorcontrib>Freire González, Mercedes</creatorcontrib><creatorcontrib>Santos Soler, Gregorio</creatorcontrib><creatorcontrib>Ruiz-Lucea, Maria Esther</creatorcontrib><creatorcontrib>Ibáñez-Barceló, Mónica</creatorcontrib><creatorcontrib>Castellví, Iván</creatorcontrib><creatorcontrib>Galisteo, Carlos</creatorcontrib><creatorcontrib>Quevedo Vila, Víctor</creatorcontrib><creatorcontrib>Raya, Enrique</creatorcontrib><creatorcontrib>Narváez, Javier</creatorcontrib><creatorcontrib>Expósito, Lorena</creatorcontrib><creatorcontrib>Hernández Beriaín, José A</creatorcontrib><creatorcontrib>Horcada, Loreto</creatorcontrib><creatorcontrib>Aurrecoechea, Elena</creatorcontrib><creatorcontrib>Pego Reigosa, José M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and Experimental Rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Riancho-Zarrabeitia, Leyre</au><au>Martínez-Taboada, Víctor M</au><au>Rúa-Figueroa, Iñigo</au><au>Alonso, Fernando</au><au>Galindo-Izquierdo, María</au><au>Ovalles, Juan</au><au>Olivé-Marqués, Alejandro</au><au>Mena Vázquez, Natalia</au><au>Calvo-Alén, Jaime</au><au>Menor Almagro, Raúl</au><au>Tomero Muriel, Eva</au><au>Uriarte Isacelaya, Esther</au><au>Boteanu, Alina</au><au>Andres, Mariano</au><au>Freire González, Mercedes</au><au>Santos Soler, Gregorio</au><au>Ruiz-Lucea, Maria Esther</au><au>Ibáñez-Barceló, Mónica</au><au>Castellví, Iván</au><au>Galisteo, Carlos</au><au>Quevedo Vila, Víctor</au><au>Raya, Enrique</au><au>Narváez, Javier</au><au>Expósito, Lorena</au><au>Hernández Beriaín, José A</au><au>Horcada, Loreto</au><au>Aurrecoechea, Elena</au><au>Pego Reigosa, José M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?</atitle><jtitle>Clinical and Experimental Rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2021-05-01</date><risdate>2021</risdate><volume>39</volume><issue>3</issue><spage>555</spage><epage>563</epage><pages>555-563</pages><issn>0392-856X</issn><eissn>1593-098X</eissn><abstract>We aimed to investigate the association between the different antiphospholipid antibodies (aPL) and both systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) manifestations.
Patients from the RELESSER registry, a Spanish retrospective, cross-sectional, forty-five hospital registry of adult SLE patients, were included.
Out of a total of 3,658 SLE patients, 1372 were aPL positive (555 of them fulfilled criteria for APS). All aPL types showed a negative association with cutaneous SLE manifestations. Lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) were both associated with haematological, ophthalmological and neuropsychiatric manifestations. IgG isotypes were associated with a higher risk of lupus manifestations compared with IgM. We found that the risk of neuropsychiatric and ophthalmological manifestations significantly increased with a higher number of positive aPL whereas the risk of cutaneous symptoms showed a negative correlation. All types of aPL, and more strongly LA, were associated with non-criteria antiphospholipid syndrome (APS) manifestations such as thrombocytopenia and haemolytic anaemia. Moreover, LA and aCL (particularly IgG isotype) were also associated with Libman-Sacks endocarditis and cognitive impairment. This association was stronger with more than one positive aPL. All types of aPL were also associated with classic APS manifestations, although LA, IgG isotypes, and patients with more than one aPL displayed a higher risk.
There is a hierarchy for aPL and the risk of APS and SLE manifestations. aCL, and especially LA, confer a higher risk for major organ involvement in SLE. IgG isotypes seem to have a more important role. The load of aPL confer a higher risk for APS and certain SLE manifestations.</abstract><cop>Italy</cop><pmid>32828148</pmid><doi>10.55563/clinexprheumatol/9kxexc</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0392-856X |
ispartof | Clinical and Experimental Rheumatology, 2021-05, Vol.39 (3), p.555-563 |
issn | 0392-856X 1593-098X |
language | eng |
recordid | cdi_proquest_miscellaneous_2436875925 |
source | Alma/SFX Local Collection |
title | Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T23%3A48%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Do%20all%20antiphospholipid%20antibodies%20confer%20the%20same%20risk%20for%20major%20organ%20involvement%20in%20systemic%20lupus%20erythematosus%20patients?&rft.jtitle=Clinical%20and%20Experimental%20Rheumatology&rft.au=Riancho-Zarrabeitia,%20Leyre&rft.date=2021-05-01&rft.volume=39&rft.issue=3&rft.spage=555&rft.epage=563&rft.pages=555-563&rft.issn=0392-856X&rft.eissn=1593-098X&rft_id=info:doi/10.55563/clinexprheumatol/9kxexc&rft_dat=%3Cproquest_cross%3E2436875925%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2436875925&rft_id=info:pmid/32828148&rfr_iscdi=true |